TY  - CONF

T1  - Abstract P4-04-06: AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers

JO  - Poster Session Abstracts

PY  - 2018/02/15

AU  - Robertson JFR

AU  - Coleman RE

AU  - Cheung KL

AU  - Evans A

AU  - Holcombe C

AU  - Skene A

AU  - Rea D

AU  - Ahmed S

AU  - Jahan A

AU  - Kelly S

AU  - Horgan K et al

ED  - 

DO  - DOI: 10.1158/1538-7445.sabcs17-p4-04-06

PB  - American Association for Cancer Research

Y2  - 2025/10/10

ER  -